1. Myelin-oligodendrocyte glycoprotein antibody-associated disease
- Author
-
Axel Petzold, Tobias Derfuss, Bruno Stankoff, Aksel Siva, Maria Pia Amato, Tanuja Chitnis, Alvaro Cobo-Calvo, Romain Marignier, Sandra Vukusic, Nasrin Asgari, Christopher Linington, Edgar Meinl, Emmanuelle Waubant, Marco Capobianco, Patrick Waters, Hans Lassmann, Ingo Kleiter, Anu Jacob, Sean J. Pittock, Mar Tintoré, Friedemann Paul, Brenda Banwell, Kumaran Deiva, Kazuo Fujihara, Jeffrey Bennett, Jacqueline Palace, Krzysztof Selmaj, Olga Ciccarelli, Anthony Traboulsee, Brian G. Weinshenker, Fabienne Brilot, Jérôme De Seze, Maria Isabel Leite, Harry Alexopoulos, Ho Jin Kim, Anne-Katrin Pröbstel, Douglas Kazutoshi Sato, Bernhard Hemmer, Markus Reindl, Yael Hacohen, and Orhan Aktas
- Subjects
Adult ,Adolescent ,CNS demyelination ,Demyelinating Autoimmune Diseases, CNS ,Disease ,Myelin oligodendrocyte glycoprotein ,Young Adult ,medicine ,Humans ,Immunologic Factors ,Spectrum disorder ,Child ,Pathological ,Autoantibodies ,Neuromyelitis optica ,biology ,business.industry ,Multiple sclerosis ,Middle Aged ,medicine.disease ,Immunology ,biology.protein ,Myelin-Oligodendrocyte Glycoprotein ,Neurology (clinical) ,Antibody ,business ,Biomarkers - Abstract
Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination. Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis, and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (NMOSD) cumulative biological, clinical, and pathological evidence discriminates between these conditions. Patients should not be diagnosed with multiple sclerosis or NMOSD if they have anti-MOG antibodies in their serum. However, many questions related to the clinical characterisation of MOGAD and pathogenetic role of MOG antibodies are still unanswered. Furthermore, therapy is mainly based on standard protocols for aquaporin-4 antibody-associated NMOSD and multiple sclerosis, and more evidence is needed regarding how and when to treat patients with MOGAD.
- Published
- 2021